{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:09:27Z","timestamp":1787497767058,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03 CA259658"],"award-info":[{"award-number":["R03 CA259658"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA290334"],"award-info":[{"award-number":["R21 CA290334"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012359","name":"Promotion and Mutual Aid Corporation for Private Schools of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Non-coding RNA Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ncrna.2025.02.003","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:38:55Z","timestamp":1740137935000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4610-721X","authenticated-orcid":false,"given":"Andrei","family":"Gurau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-7112","authenticated-orcid":false,"given":"Suguru","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9946-6698","authenticated-orcid":false,"given":"Kaitlyn","family":"Ecoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen P.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Eshleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Conover Talbot","family":"Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valsamo","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Brock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-0134","authenticated-orcid":false,"given":"Yuping","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncrna.2025.02.003_bib1","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future","volume":"9","author":"Nicolini","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New Era for malignant pleural mesothelioma: updates on therapeutic options","volume":"40","author":"Tsao","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3892\/mco.2022.2522","article-title":"C. Genova, Novel approaches for the treatment of unresectable malignant pleural mesothelioma: a focus on immunotherapy and target therapy (Review)","volume":"16","author":"Rijavec","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057663","article-title":"Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial","volume":"12","author":"Kok","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ncrna.2025.02.003_bib6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ncrna.2025.02.003_bib7","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1200\/JCO.2020.38.15_suppl.9003","article-title":"PrE0505: phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)\u2014a PrECOG LLC study","volume":"38","author":"Forde","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8599","article-title":"DREAM3R: durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma\u2014a phase 3 randomized trial","volume":"40","author":"Forde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100644","article-title":"Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma","volume":"7","author":"Canova","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ncrna.2025.02.003_bib10","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-17-0235","article-title":"Cisplatin alters antitumor immunity and synergizes with PD-1\/PD-L1 inhibition in head and neck squamous cell carcinoma","volume":"5","author":"Tran","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ncrna.2025.02.003_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114680","article-title":"The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022","volume":"243","author":"Su","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ncrna.2025.02.003_bib12","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03bab to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ncrna.2025.02.003_bib13","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.21873\/anticanres.13281","article-title":"Cisplatin augments antitumor T-cell responses leading to a potent therapeutic effect in combination with PD-L1 blockade","volume":"39","author":"Wakita","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ncrna.2025.02.003_bib14","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190362","article-title":"Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1\/2-AP-1 signaling pathway","volume":"39","author":"Tsai","year":"2019","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ncrna.2025.02.003_bib15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3390\/cancers12030666","article-title":"Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer","volume":"12","author":"Cavazzoni","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ncrna.2025.02.003_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001392","article-title":"Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy","volume":"8","author":"Lu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ncrna.2025.02.003_bib17","doi-asserted-by":"crossref","first-page":"S527","DOI":"10.1016\/j.jtho.2018.08.722","article-title":"P1.04-07 pemetrexed enhances anti-tumor efficacy of PD-L1 blockade by promoting intra-tumor immune response via tumor and T cell-intrinsic mechanisms","volume":"13","author":"Schaer","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib18","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1158\/1078-0432.CCR-19-0433","article-title":"The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy","volume":"25","author":"Schaer","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ncrna.2025.02.003_bib19","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/ncomms8316","article-title":"A piRNA-like small RNA interacts with and modulates p-ERM proteins in human somatic cells","volume":"6","author":"Mei","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ncrna.2025.02.003_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.omtn.2017.01.003","article-title":"A piRNA-like small RNA induces chemoresistance to cisplatin-based therapy by inhibiting apoptosis in lung squamous cell carcinoma","volume":"6","author":"Wang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ncrna.2025.02.003_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2017.03.017","article-title":"A phosphorylation-wide sncRNA screen reveals Protein Functional Effector sncRNAs (pfeRNAs) in human lung somatic cells","volume":"396","author":"Gable","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ncrna.2025.02.003_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.canlet.2017.06.013","article-title":"Protein functional effector sncRNAs (pfeRNAs) in lung cancer","volume":"403","author":"Brock","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ncrna.2025.02.003_bib23","first-page":"80","article-title":"A cost-effective and non-invasive pfeRNA-based test differentiates benign and suspicious pulmonary nodules from malignant ones","volume":"7","author":"Liu","year":"2021","journal-title":"Noncoding RNA"},{"key":"10.1016\/j.ncrna.2025.02.003_bib24","doi-asserted-by":"crossref","first-page":"6778","DOI":"10.1038\/s41598-022-10800-0","article-title":"A TRIzol-based method for high recovery of plasma sncRNAs approximately 30 to 60 nucleotides","volume":"12","author":"Rodgers","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ncrna.2025.02.003_bib25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jss.2022.12.002","article-title":"pfeRNAs-A novel class of small non-coding RNAs with real translational potential","volume":"284","author":"Mei","year":"2023","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.ncrna.2025.02.003_bib26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S1470-2045(15)00048-0","article-title":"A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib27","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1373\/clinchem.2015.239459","article-title":"Data normalization strategies for MicroRNA quantification","volume":"61","author":"Schwarzenbach","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ncrna.2025.02.003_bib28","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","article-title":"Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer","volume":"25","author":"Azuma","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41389-020-00257-z","article-title":"Targeting PD-L1 in non-small cell lung cancer using CAR T cells","volume":"9","author":"Liu","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ncrna.2025.02.003_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib31","article-title":"Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib32","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/14712598.2019.1635115","article-title":"Durvalumab in cancer medicine: a comprehensive review","volume":"19","author":"Alvarez-Argote","year":"2019","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.ncrna.2025.02.003_bib33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s11523-021-00843-0","article-title":"A review in extensive-stage SCLC","volume":"16","author":"Al-Salama","year":"2021","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib34","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.2217\/fon-2022-0093","article-title":"MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer","volume":"18","author":"Janjigian","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.ncrna.2025.02.003_bib35","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.cllc.2021.09.010","volume":"23","author":"Heymach","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ncrna.2025.02.003_bib36","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/cncr.34930","article-title":"A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma","volume":"129","author":"Patel","year":"2023","journal-title":"Cancer"}],"container-title":["Non-coding RNA Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468054025000253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468054025000253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:15:04Z","timestamp":1748650504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468054025000253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":36,"alternative-id":["S2468054025000253"],"URL":"https:\/\/doi.org\/10.1016\/j.ncrna.2025.02.003","relation":{},"ISSN":["2468-0540"],"issn-type":[{"value":"2468-0540","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy","name":"articletitle","label":"Article Title"},{"value":"Non-coding RNA Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncrna.2025.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}